AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25335172 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 169
Study 25335172 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 169
Study 22507091 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell Block (CB) method
Number of subjects: 170
Study 22507091 — intervention group
Group type: COMPARATOR
Intervention: Smear cytology
Number of subjects: 170
Study 20420616 — intervention group
Group type: COMPARATOR
Intervention: Continuous venovenous hemodiafiltration (CVVHDF)
Number of subjects: 60
Study 20420616 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained hemodiafiltration (S-HDF)
Number of subjects: 60
Study 18696354 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 0
Study 18696354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16101852 — intervention group
Group type: EXPERIMENTAL
Intervention: Resident-oriented care model
Number of subjects: 0
Study 12269877 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolic acid peels combined with modified Kligman's formula (hydroquinone 5%, tretinoin 0.05%, hydrocortisone acetate 1%)
Number of subjects: 40
Study 12269877 — intervention group
Group type: COMPARATOR
Intervention: Modified Kligman's formula (hydroquinone 5%, tretinoin 0.05%, hydrocortisone acetate 1%)
Number of subjects: 40
Study 10073637 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibasoft contact lens
Number of subjects: 10
Study 10073637 — intervention group
Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 10
Study 10073637 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue contact lens
Number of subjects: 10
Study 10073637 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomedics contact lens
Number of subjects: 10
Study 8672931 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous i.v.‐tocolysis and oral application of magnesium sulfate
Number of subjects: 59
Study 8672931 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous i.v.‐tocolysis and i.v.‐application of magnesium sulfate
Number of subjects: 59
Study 8672931 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile i.v.‐application of fenoterol (bolus tocolysis) and oral application of magnesium sulfate
Number of subjects: 59
Study 1828309 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg
Number of subjects: 52
Study 1828309 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 4 mg/kg
Number of subjects: 52
Study 7104157 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 16
Study 7104157 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 16
Study 7104157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30958026 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal-contingent recording
Number of subjects: 286
Study 30958026 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-contingent recording
Number of subjects: 286
Study 29928989 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score for veno-occlusive disease (VOD)
Number of subjects: 13097
Study 29928989 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloablative conditioning regimens
Number of subjects: 13097
Study 29928989 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan-based myeloablative conditioning regimens guided by pharmacokinetic monitoring
Number of subjects: 13097
Study 29928989 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretransplant risk score
Number of subjects: 13097
Study 27834446 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVH-HCO
Number of subjects: 0
Study 27834446 — intervention group
Group type: COMPARATOR
Intervention: CVVH-Std
Number of subjects: 0
Study 24623502 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepilex Lite dressings
Number of subjects: 50
Study 24623502 — intervention group
Group type: COMPARATOR
Intervention: Vaseline gauze care
Number of subjects: 50
Study 23158128 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine alone
Number of subjects: 120
Study 23158128 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine plus fentanyl 1 µg/ml
Number of subjects: 120
Study 23158128 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine plus fentanyl 2 µg/ml
Number of subjects: 120
Study 23158128 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine plus fentanyl 3 µg/ml
Number of subjects: 120
Study 20631056 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education booklet and BP tracker
Number of subjects: 109
Study 20631056 — intervention group
Group type: COMPARATOR
Intervention: Standard approach of hypertension information leaflet
Number of subjects: 109
Study 17196293 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon/ribavirin therapy
Number of subjects: 1144
Study 15734599 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 80
Study 15734599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 12472620 — intervention group
Group type: EXPERIMENTAL
Intervention: Maca Gelatinizada 1,500 mg
Number of subjects: 100
Study 12472620 — intervention group
Group type: EXPERIMENTAL
Intervention: Maca Gelatinizada 3,000 mg
Number of subjects: 100
Study 12472620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9696953 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg daily for 6 days)
Number of subjects: 8
Study 9696953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg daily for 6 days)
Number of subjects: 8
Study 9696953 — intervention group
Group type: COMPARATOR
Intervention: Control (Furosemide 20 mg intravenously)
Number of subjects: 8
Study 7864501 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E treatment
Number of subjects: 20
Study 2684076 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular LEFAC (bovine liver extract containing folic acid and cyanocobalamin)
Number of subjects: 15
Study 2684076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31135817 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab, 120 mg
Number of subjects: 168
Study 31135817 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab, 240 mg
Number of subjects: 168
Study 31135817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 29098381 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 1500-mg administered orally once daily on study days 4 through 11
Number of subjects: 24
Study 26239482 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and albuterol
Number of subjects: 0
Study 26239482 — intervention group
Group type: COMPARATOR
Intervention: Albuterol
Number of subjects: 0
Study 23426660 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in the morning followed by a night of sleep
Number of subjects: 32
Study 23426660 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in the evening followed by a night of sleep
Number of subjects: 32
Study 21282539 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (one infusion at 7 × (glomerular filtration rate + 25) based on EDTA)
Number of subjects: 1447
Study 21282539 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (at least 99% of the 7 × AUC dose)
Number of subjects: 1447
Study 21282539 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (lower doses)
Number of subjects: 1447
Study 21282539 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 1447
Study 21282539 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 1447
Study 20137694 — intervention group
Group type: EXPERIMENTAL
Intervention: 52-week rabeprazole treatment
Number of subjects: 98
Study 16944825 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized exercises
Number of subjects: 30
Study 16944825 — intervention group
Group type: COMPARATOR
Intervention: Standard exercises
Number of subjects: 30
Study 16944825 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Customized and Standard)
Number of subjects: 30
Study 15210659 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 18
Study 15210659 — intervention group
Group type: COMPARATOR
Intervention: No Theophylline (Control)
Number of subjects: 18
Study 11259888 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg potassium diclofenac orally 1 hour preoperatively and placebo 30 minutes postoperatively (Preop group)
Number of subjects: 127
Study 11259888 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg potassium diclofenac 1 hour preoperatively and 25 mg diclofenac 30 minutes postoperatively (Pre+postop group)
Number of subjects: 127
Study 11259888 — intervention group
Group type: COMPARATOR
Intervention: Placebo 1 hour preoperatively and 50 mg potassium diclofenac 30 minutes postoperatively (Postop group)
Number of subjects: 127
Study 9140151 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C-urea breath test (UBT) with 75 mg 13C-urea and citric acid
Number of subjects: 77
Study 9140151 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C-urea breath test (UBT)
Number of subjects: 77
Study 9140151 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fasting conditions
Number of subjects: 77
Study 8315437 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.5 mg to 2 mg per day)
Number of subjects: 57
Study 8315437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 3802713 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) 50 mg
Number of subjects: 14
Study 3802713 — intervention group
Group type: EXPERIMENTAL
Intervention: E-10-hydroxynortriptyline (E-10-OH-NT)
Number of subjects: 14
Study 3802713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 29150957 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenogeneic bone block loaded with rhBMP‐2 (test)
Number of subjects: 24
Study 29150957 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone block (control)
Number of subjects: 24
Study 27754881 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin T algorithm
Number of subjects: 2222
Study 27754881 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I algorithm
Number of subjects: 2222
Study 25301763 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 12
Study 25301763 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tDCS
Number of subjects: 12
Study 25301763 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 12
Study 22980158 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention consisting of four educational sessions over 4 consecutive weeks
Number of subjects: 200
Study 22980158 — intervention group
Group type: COMPARATOR
Intervention: Traditional education method (Control group)
Number of subjects: 200
Study 20151824 — intervention group
Group type: EXPERIMENTAL
Intervention: T4‐WD Group (levothyroxine withdrawal for 4 weeks)
Number of subjects: 291
Study 20151824 — intervention group
Group type: EXPERIMENTAL
Intervention: T3‐WD Group (levothyroxine withdrawal for 4 weeks plus 2 weeks on and then 2 weeks off liothyronine)
Number of subjects: 291
Study 20151824 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTSH Group (recombinant human thyroid-stimulating hormone administration)
Number of subjects: 291
Study 20151824 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTSH Group
Number of subjects: 291
Study 20151824 — intervention group
Group type: COMPARATOR
Intervention: T4‐WD Group
Number of subjects: 291
Study 20151824 — intervention group
Group type: COMPARATOR
Intervention: T3‐WD Group
Number of subjects: 291
Study 18292586 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with dendritic cells pulsed with two MAGE‐A3 antigenic peptides (HLA‐A1 and HLA‐DP4)
Number of subjects: 2
Study 18292586 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with dendritic cells pulsed with two MAGE‐A3 antigenic peptides
Number of subjects: 2
Study 15795446 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron treatment (125 mg FeSO(4) plus ascorbate and folate)
Number of subjects: 81
Study 15795446 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (25 mg ascorbic acid and 10 microg folate)
Number of subjects: 81
Study 15795446 — intervention group
Group type: COMPARATOR
Intervention: Nonanemic controls
Number of subjects: 81
Study 15795446 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemic mothers (both treatment and placebo)
Number of subjects: 81
Study 12716806 — intervention group
Group type: EXPERIMENTAL
Intervention: Action stages (healthy eating intervention)
Number of subjects: 768
Study 12716806 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemplation stage (healthy eating intervention)
Number of subjects: 768
Study 12716806 — intervention group
Group type: EXPERIMENTAL
Intervention: Precontemplators (healthy eating intervention)
Number of subjects: 768
Study 10378240 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM) intervention
Number of subjects: 67
Study 10378240 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 67
Study 8649493 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether
Number of subjects: 560
Study 8649493 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 560
Study 1906433 — intervention group
Group type: EXPERIMENTAL
Intervention: Blacil preparation (20 mg disodium cromoglycate)
Number of subjects: 16
Study 1906433 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomudal preparation (20 mg disodium cromoglycate)
Number of subjects: 16
Study 1906433 — intervention group
Group type: COMPARATOR
Intervention: Both preparations (Blacil and Lomudal)
Number of subjects: 16
Study 6357208 — intervention group
Group type: EXPERIMENTAL
Intervention: suprofen 200 mg
Number of subjects: 130
Study 6357208 — intervention group
Group type: EXPERIMENTAL
Intervention: suprofen 400 mg
Number of subjects: 130
Study 6357208 — intervention group
Group type: EXPERIMENTAL
Intervention: diflunisal 750 mg
Number of subjects: 130
Study 6357208 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 130
Study 31311060 — intervention group
Group type: EXPERIMENTAL
Intervention: Join the Healthy Boat intervention
Number of subjects: 1739
Study 31825026 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish applied every 3 months
Number of subjects: 157
Study 31825026 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish applied every 6 months
Number of subjects: 157
Study 31825026 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluoride varnish)
Number of subjects: 157
Study 27823821 — intervention group
Group type: EXPERIMENTAL
Intervention: Single fraction of 19Gy
Number of subjects: 170
Study 27823821 — intervention group
Group type: EXPERIMENTAL
Intervention: Two fractions of 13.5Gy
Number of subjects: 170
Study 25733083 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Imagery CD for 18 min
Number of subjects: 62
Study 25733083 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 62
Study 23640612 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/brimonidine 0.2% fixed combination (BBFC)
Number of subjects: 1350
Study 23640612 — intervention group
Group type: COMPARATOR
Intervention: Brinzolamide monotherapy
Number of subjects: 1350
Study 23640612 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine monotherapy
Number of subjects: 1350
Study 21561700 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg per day for patients below 50 kg and 100 mg per day for patients over 50 kg)
Number of subjects: 150
Study 21561700 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 150
Study 19139220 — intervention group
Group type: EXPERIMENTAL
Intervention: Videophone intervention
Number of subjects: 148
Study 19139220 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention
Number of subjects: 148
Study 19139220 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 148
Study 19139220 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (videophone and telephone)
Number of subjects: 148
Study 17196519 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols combined with exercise
Number of subjects: 84
Study 17196519 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols
Number of subjects: 84
Study 17196519 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 84
Study 17196519 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 84
Study 16123091 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 50
Study 16123091 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 50
Study 16123091 — intervention group
Group type: COMPARATOR
Intervention: Control (Healthy subjects)
Number of subjects: 50
Study 12192663 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV patients on anti-viral medication
Number of subjects: 14
Study 12192663 — intervention group
Group type: COMPARATOR
Intervention: Control group (unaffected matched controls)
Number of subjects: 14
Study 10206449 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-6 (90 microg i.v.)
Number of subjects: 21
Study 10206449 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (100 microg i.v.)
Number of subjects: 21
Study 10206449 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-6 + GHRH
Number of subjects: 21
Study 7551660 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate alone (MTX), n = 12
Number of subjects: 26
Study 7551660 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate + Sulphasalazine (MTX + SASP), n = 14
Number of subjects: 26
Study 7551660 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 26
Study 2192197 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 72 hour infusion (CI) of Adriamycin, 60 mg/m2 every 3 weeks
Number of subjects: 47
Study 2192197 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bolus (B) of Adriamycin, 60 mg/m2 every 3 weeks
Number of subjects: 47
Study 715133 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback group (attempted to increase and decrease heart rate with visual display)
Number of subjects: 30
Study 715133 — intervention group
Group type: EXPERIMENTAL
Intervention: No-feedback group (attempted to increase and decrease heart rate without visual display)
Number of subjects: 30
Study 715133 — intervention group
Group type: COMPARATOR
Intervention: Tracking group (merely tracked a visual analog display of heart rate)
Number of subjects: 30
Study 715133 — intervention group
Group type: EXPERIMENTAL
Intervention: High cold‐pressor reactors
Number of subjects: 30
Study 715133 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cold‐pressor reactors
Number of subjects: 30
Study 715133 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary-prone personality characteristics (measured by Jenkins Activity Scale)
Number of subjects: 30
Study 31129369 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss smartphone app (APP)
Number of subjects: 400
Study 31129369 — intervention group
Group type: COMPARATOR
Intervention: App plus weekly coaching (APP + C)
Number of subjects: 400
Study 31129369 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-responders re-randomized to step-up treatment
Number of subjects: 400
Study 28167311 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training program (including pre-study e-learning and simulation)
Number of subjects: 81
Study 28167311 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 81
Study 28167311 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training program
Number of subjects: 81
Study 24905489 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA)
Number of subjects: 64
Study 24905489 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (S)
Number of subjects: 64
Study 23490041 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel load
Number of subjects: 156
Study 23490041 — intervention group
Group type: COMPARATOR
Intervention: 300 mg clopidogrel load
Number of subjects: 156
Study 23490041 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin reload (80 mg + 40 mg)
Number of subjects: 156
Study 23490041 — intervention group
Group type: COMPARATOR
Intervention: No statin reload
Number of subjects: 156
Study 23490041 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel load (secondary endpoint)
Number of subjects: 156
Study 23490041 — intervention group
Group type: COMPARATOR
Intervention: 300 mg clopidogrel load (secondary endpoint)
Number of subjects: 156
Study 22117691 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise and support programme
Number of subjects: 156
Study 22117691 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention
Number of subjects: 156
Study 19220558 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain plasticity-based computerized cognitive training program
Number of subjects: 487
Study 19220558 — intervention group
Group type: COMPARATOR
Intervention: General cognitive stimulation program (active control)
Number of subjects: 487
Study 17613274 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination tablets (600mg calcium + 300mg magnesium + 100IU vitamin D3)
Number of subjects: 15
Study 17613274 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate tablets (1000mg calcium)
Number of subjects: 15
Study 17613274 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 15
Study 15491318 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonicare Elite
Number of subjects: 45
Study 15491318 — intervention group
Group type: COMPARATOR
Intervention: Sonicare Advance
Number of subjects: 45
Study 11479391 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.2 mg/kg) + L-Dopa (2 mg/kg per h)
Number of subjects: 5
Study 11479391 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.2 mg/kg)
Number of subjects: 5
Study 9758296 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinsertion of the stylet before needle removal
Number of subjects: 600